A Clinical Study of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy Patients: A New Frontier

Sharma, Alok; Sane, Hemangi; Gokulchandran, Nandini; Kulkarni, Pooja; Gandhi, Sushant; Sundaram, Jyothi; Paranjape, Amruta; Shetty, Akhil; Bhagwanani, Khushboo; Biju, Hema; Badhe, Prerna

doi:10.1155/2015/905874

Cited by 51 publications

(52 citation statements)

References 32 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the symptoms associated with CP and coexisting conditions can be managed with a comprehensive treatment plan that addresses the child's primary, secondary and coexisting factors which can help the child live a better life [9]. It has been observed that cellular therapy can be safe and effective in repairing the damage to the neural tissue [10,11].…”

Section: Discussionmentioning

confidence: 99%

Intrathecal Administration of Autologous Bone Marrow Mononuclear Cells in a Case of Cerebral Palsy Coexisting with Autistic Features?

Pai¹

2017

Phys Med Rehabil Int

View full text Add to dashboard Cite

Cerebral palsy (CP) represents a group of developmental disorders leading to neurodisability in the pediatric population. The 2008 Autism and Developmental Disabilities Monitoring Network (ADDM) CP Network revealed that nearly 7% of children with CP co-existed with autistic disorders. Here we present a case report of a six and a half year old child who presented with CP coexisting with autistic features. She underwent two cellular therapies with autologous bone marrow mononuclear administered intrathecally, followed by intensive neurorehabilitation. Over the span of 15 months post cellular therapies, improvements were seen in the walking balance, sitting tolerance, eye contact, clarity of speech, social interaction and voluntary control of the left upper limb with increased weight bearing capacity. There was a decrease from 96 to 82 on the ISAA scale. CARS score reduced from 30.5 to 25 after the two cellular therapies. GMFM score showed an improvement from 64.31% to 79.96% and FIM increased from 40 to 49. No adverse events were observed. This case report supports the evidences suggesting that cellular therapy along with rehabilitation augments the recovery processes in patients with CP coexisting with autistic features. Further clinical studies are required to establish the therapeutic potential of cellular therapy taking into consideration the multifaceted symptomatic presentations in CP.

show abstract

Section: Discussionmentioning

confidence: 99%

Intrathecal Administration of Autologous Bone Marrow Mononuclear Cells in a Case of Cerebral Palsy Coexisting with Autistic Features?

Pai¹

2017

Phys Med Rehabil Int

View full text Add to dashboard Cite

show abstract

“…They suggested that autologous BM-MSC transplantation may be a feasible, safe, and effective therapy for patients with CP. The treatment improved the development of motor function in children with CP (84). After providing informed consent, 52 patients with CP who met the study criteria received BM-MSC transplantation.…”

Section: Clinical Application Of Ucbcs Therapy For Ischemic Brain Injurymentioning

confidence: 99%

Future perspectives of cell therapy for neonatal hypoxic–ischemic encephalopathy

2017

View full text Add to dashboard Cite

Neonatal ischemic brain injury causes permanent motor-deficit cerebral palsy. Hypoxic-ischemic encephalopathy (HIE) is a very serious condition that can result in death and disability. In 1997, we reported that irreversible neuronal cell damage is induced by the elevation of intracellular Ca ion concentration that has occurred in sequence after excess accumulation of the excitatory neurotransmitter glutamate during ischemia. We also reported that hypothermia was effective in treating ischemic brain damage in rats by suppressing energy loss and raising intracellular Ca ion concentration. Following the 2010 revised International Liaison Committee on Resuscitation guideline, our group developed the Guideline for the treatment of Hypothermia in Japan, and we started online case registry in January 2012. However, therapeutic hypothermia must be initiated within the first 6 h after birth. By contrast, cell therapy may have a much longer therapeutic time window because it might reduce apoptosis/oxidative stress and enhance the regenerative process. In 2014, we administered autologous umbilical cord blood stem cell (UCBC) therapy for neonatal HIE, for the first time in Japan. We enrolled five full-term newborns with moderate-to-severe HIE. Our autologous UCBC therapy is leading to new protocols for the prevention of ischemic brain damage.

show abstract

“…The growth factors secreted by these cells also help in remyelination, synaptogenesis, cytoprotection and angiogenesis which reverse the cellular injury in CP [18,19]. Numerous preclinical studies have In 2015, we published a nonrandomized study demonstrating the benefits of autologous bone marrow mononuclear cells (BMMNCs) in cerebral palsy [27]. These patients were followed up at 3 and 6 months.…”

Section: Stem Cell Therapy In Cerebral Palsymentioning

confidence: 99%

Stem Cell Therapy in Pediatric Neurological Disabilities

Sharma¹,

Sane²,

Gokulchandran³

et al. 2017

Physical Disabilities - Therapeutic Implications

Self Cite

View full text Add to dashboard Cite

Pediatric neurological disorders represent a major part of the disabilities worldwide. In over 10 decades of research to find a cure for these disorders, medical science has not been able to repair the underlying brain injury. This chapter focuses on recent advances in the application of stem cells as a therapeutic tool for some of the common neurodevelopmental disorders (cerebral palsy, autism, intellectual disability and muscular dystrophy). The mechanism of action of stem cells in each disorder has been explained. A review of clinical data has been described giving a clear understanding of current status of stem cell therapy in these disorders. Various factors influencing the outcome of stem cell therapy such as different types of cells, different routes of administration and dosage and frequency of transplantation have also been discussed. Our experience of treating these disorders is exhibited in the form of our published data. Use of novel monitoring tools such as MRI MSK and PET-CT scan brain to track the changes occurring at cellular level after stem cell therapy are described. We also highlight the importance of a multidisciplinary approach of combining rehabilitation with stem cell therapy.

show abstract

A Clinical Study of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy Patients: A New Frontier

Cited by 51 publications

References 32 publications

Intrathecal Administration of Autologous Bone Marrow Mononuclear Cells in a Case of Cerebral Palsy Coexisting with Autistic Features?

Intrathecal Administration of Autologous Bone Marrow Mononuclear Cells in a Case of Cerebral Palsy Coexisting with Autistic Features?

Future perspectives of cell therapy for neonatal hypoxic–ischemic encephalopathy

Stem Cell Therapy in Pediatric Neurological Disabilities

Contact Info

Product

Resources

About